{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:59:05Z","timestamp":1787317145258,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.acvd.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:47:42Z","timestamp":1512172062000},"page":"634-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact"],"prefix":"10.1016","volume":"111","author":[{"given":"Christophe","family":"Bauters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Meurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hennebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2017.07.007_bib0160","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2017.07.007_bib0165","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2017.07.007_bib0170","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2017.07.007_bib0175","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0180","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2017.07.007_bib0185","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0190","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MOL.0000000000000230","article-title":"Long-term follow-up of lipid-lowering trials","volume":"26","author":"Packard","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0195","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamainternmed.2016.2751","article-title":"Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment","volume":"176","author":"Leibowitz","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.acvd.2017.07.007_bib0200","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.12.019","article-title":"Prognosis of patients with stable coronary artery disease (from the CORONOR study)","volume":"113","author":"Bauters","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","article-title":"Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease","volume":"64","author":"Hamon","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0210","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2017.07.007_bib0215","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2017.07.007_bib0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","author":"Gitt","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2017.07.007_bib0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.acvd.2016.11.004","article-title":"Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS\/CHD study","volume":"110","author":"Ferrieres","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2017.07.007_bib0230","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0235","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ahj.2011.03.023","article-title":"Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines","volume":"161","author":"Virani","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2017.07.007_bib0240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijcard.2016.04.182","article-title":"A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction","volume":"217","author":"Bauters","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0245","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryden","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2017.07.007_bib0250","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.acvd.2015.01.007","article-title":"Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease","volume":"108","author":"Meurice","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2017.07.007_bib0255","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2017.07.007_bib0260","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2017.07.007_bib0265","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2017.02.050","article-title":"Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease","volume":"69","author":"Lemesle","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0270","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2017.07.007_bib0275","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2017.07.007_bib0280","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2017.07.007_bib0285","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","article-title":"The relationship between cholesterol and survival in patients with chronic heart failure","volume":"42","author":"Rauchhaus","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.acvd.2016.04.003","article-title":"Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients","volume":"110","author":"Lamblin","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2017.07.007_bib0295","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2017.07.007_bib0300","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2017.07.007_bib0305","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2017.07.007_bib0310","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","article-title":"Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial","volume":"378","author":"Bulbulia","year":"2011","journal-title":"Lancet"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213617302255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213617302255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:45:14Z","timestamp":1761745514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213617302255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1875213617302255"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2017.07.007","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}